About Cabozantinib HCl API

Mecanismo de acción

Cabozantinib is a tyrosine kinase inhibitor that acts by blocking the activity of multiple tyrosine kinases, including MET and VEGFR2. Tyrosine kinases are enzymes that play a key role in signaling pathways that regulate cellular processes such as proliferation, migration, and angiogenesis.

In cancer, these signaling pathways are often dysregulated, leading to uncontrolled cell growth and survival. By inhibiting the activity of these kinases, cabozantinib can block these signaling pathways and potentially slow or stop the growth of cancer cells.

Specifically, cabozantinib has been shown to effectively inhibit the activity of MET, a tyrosine kinase that is overexpressed in many cancers and plays a key role in tumor growth, invasion, and angiogenesis. Inhibition of VEGFR2, another target of cabozantinib, can also block the growth of new blood vessels that tumors need to grow and spread.

Overall, the mechanism of action of cabozantinib involves blocking the activity of multiple tyrosine kinases involved in cancer cell growth and survival, ultimately leading to the inhibition of tumor growth.

Indicación

Cabozantinib is an FDA-approved treatment for several types of cancer. It is indicated for the following indications:

Metastatic Renal Cell Carcinoma (mRCC): Cabozantinib is indicated for the treatment of patients with advanced or metastatic renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

Medullary Thyroid Cancer (MTC): Cabozantinib is indicated for the treatment of patients with locally advanced or metastatic medullary thyroid cancer (MTC) who require systemic therapy and have received prior treatment with radioactive iodine.

Hormone-Relapsed Prostate Cancer: Cabozantinib is indicated for the treatment of patients with hormone-relapsed prostate cancer that has progressed during or after androgen deprivation therapy.

Advanced Liver Cancer: Cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Experiencia de Dr. Reddy

Con sede en Hyderabad, India, Dr. Reddy's Laboratories es uno de los principales proveedores de ingredientes farmacéuticos activos (API) a nivel mundial. El negocio API de Dr. Reddy es considerado como un socio preferido de las compañías farmacéuticas en los Estados Unidos, Europa, Brasil, América Latina, Japón, China, Corea y los mercados emergentes.

El negocio de API de Dr. Reddy se nutre de las fortalezas técnicas profundas establecidas en los últimos 30 años en el desarrollo y fabricación de API complejas como esteroides, péptidos, moléculas complejas de cadena larga y API altamente potentes (HPAPI / medicamentos oncológicos). Esta experiencia se complementa con nuestra destreza en propiedad intelectual y asuntos regulatorios que nos ayudan a cumplir y superar los estándares regulatorios de manera consistente. Los APIs de Dr. Reddy´s Cabozantinib HCl es el resultado de la amplia experiencia en R&D, IP y Normatividad Aplicable.

Un componente clave para ayudar a nuestros clientes a ser los primeros en comercializar es una cadena de suministro receptiva. Logramos esto al asegurarnos de que todas nuestras instalaciones funcionen de manera eficiente y con los últimos estándares de calidad, seguridad y productividad. Una fuerte interconexión entre las empresas y las fábricas permite una reacción rápida a los cambios dinámicos del mercado, de modo que podamos evitar la escasez y satisfacer los repentinos aumentos de la demanda.